{"doi":"10.1002/ejhf.3263","title":"Dapagliflozin and Quality of Life Measured Using the EuroQol 5-Dimension Questionnaire in Patients with Heart Failure with Reduced and Mildly Reduced/Preserved Ejection Fraction","abstract":"AIMS: Although much is known about the usefulness of heart failure (HF)-specific instruments for assessing patient well-being, less is known about the value of generic instruments for the measurement of health-related quality of life (HRQL) in HF. The aim of this study was to assess the relationship between the EuroQol 5-dimension 5-level (EQ-5D-5L) visual analogue scale (VAS) and index scores, clinical characteristics, and outcomes in patients with HF and the effect of dapagliflozin on these scores. METHODS AND RESULTS: We performed a patient-level pooled analysis of the DAPA-HF and DELIVER trials, which investigated the effectiveness and safety of dapagliflozin in patients with HF and reduced ejection fraction (HFrEF) and mildly reduced/preserved ejection fraction (HFmrEF/HFpEF), respectively. Patients reporting higher (better) EQ-5D-5L VAS and index scores had a lower prevalence of comorbidities, including atrial fibrillation and hypertension, than patients with a worse score. They were also more likely to have better investigator-reported (New York Heart Association class) and patient-self-reported (Kansas City Cardiomyopathy Questionnaire) health status and lower median N-terminal pro-B-type natriuretic peptide levels. Compared to patients with the lowest scores (Q1), those with higher EQ-5D-5L VAS scores had better outcomes: the hazard ratio for the composite of cardiovascular death or worsening HF was 0.81 (95% confidence interval 0.72-0.91) in Q2, 0.74 (0.65-0.84) in Q3, and 0.62 (0.54-0.72) in Q4. The risk of each component of the composite outcome, and all-cause death, was also lower in patients with better scores. Similar findings were observed for the index score. Treatment with dapagliflozin improved both EQ-5D-5L VAS and index scores across the range of ejection fraction. CONCLUSIONS: Both higher (better) EQ-5D-5L VAS and index scores were associated with better outcomes. Dapagliflozin treatment improved EQ-5D-5L VAS and index scores, irrespective of ejection fraction.","journal":"European Journal of Heart Failure","year":2024,"id":432976,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":14,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9567,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":859434,"name":"Toru Kondo","orcid":"0000-0001-6853-7574","position":1,"is_corresponding":false},{"id":1237924,"name":"Atefeh Talebi","orcid":"0000-0002-8144-9074","position":2,"is_corresponding":false},{"id":57280,"name":"Pardeep S. Jhund","orcid":"0000-0003-4306-5317","position":3,"is_corresponding":false},{"id":57279,"name":"Kieran F. Docherty","orcid":"0000-0002-5446-9969","position":4,"is_corresponding":false},{"id":28286,"name":"Brian Claggett","orcid":"0000-0002-4215-9218","position":5,"is_corresponding":false},{"id":61406,"name":"Muthiah Vaduganathan","orcid":"0000-0003-0885-1953","position":6,"is_corresponding":false},{"id":844535,"name":"Erasmus Bachus","orcid":"0000-0001-8665-6892","position":7,"is_corresponding":false},{"id":51666,"name":"Adrian F. Hernandez","orcid":"0000-0003-3387-9616","position":8,"is_corresponding":false},{"id":49640,"name":"Carolyn S.P. Lam","orcid":"0000-0003-1903-0018","position":9,"is_corresponding":false},{"id":57254,"name":"Silvio E. Inzucchi","orcid":"0000-0003-1254-6636","position":10,"is_corresponding":false},{"id":57285,"name":"Felipe A. Martínez","orcid":"0000-0002-5836-972X","position":11,"is_corresponding":false},{"id":55735,"name":"Rudolf A. de Boer","orcid":"0000-0002-4775-9140","position":12,"is_corresponding":false},{"id":57284,"name":"Mikhail Kosiborod","orcid":"0000-0002-3750-9789","position":13,"is_corresponding":false},{"id":57261,"name":"Akshay S. Desai","orcid":"0000-0002-1443-0701","position":14,"is_corresponding":false},{"id":2621,"name":"Lars Køber","orcid":"0000-0002-6635-1466","position":15,"is_corresponding":false},{"id":2670,"name":"Piotr Ponikowski","orcid":"0000-0002-3391-7064","position":16,"is_corresponding":false},{"id":50019,"name":"Marc S. Sabatine","orcid":"0000-0002-0691-3359","position":17,"is_corresponding":false},{"id":27970,"name":"Scott D. Solomon","orcid":"0000-0003-3698-9597","position":18,"is_corresponding":false},{"id":2612,"name":"John J.V. McMurray","orcid":"0000-0002-6317-3975","position":19,"is_corresponding":false},{"id":2808,"name":"Mingming Yang","orcid":"0000-0003-4484-0979","position":0,"is_corresponding":true}],"reference_count":48,"raw_metadata":null,"created_at":"2026-07-19T01:59:39.937122Z","pmid":"38700986","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}